Pesquisar
Regenxbio Inc
RGNXAdicionar à lista de desejos
5.650USD
-0.070-1.22%
Fechamento 05/18, 16:00（ET）Cotações atrasadas em 15 min
291.64MValor de mercado
PerdaP/L TTM
Mais detalhes de Regenxbio Inc Empresa
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Informações de Regenxbio Inc
Código da empresaRGNX
Nome da EmpresaRegenxbio Inc
Data de listagemSep 17, 2015
CEOSimpson (Curran M)
Número de funcionários353
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 17
Endereço9804 Medical Center Drive
CidadeROCKVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20850
Telefone12405528181
Sitehttps://regenxbio.com/
Código da empresaRGNX
Data de listagemSep 17, 2015
CEOSimpson (Curran M)
Executivos da empresa Regenxbio Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
45.81K
-165.45%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
22.06K
+9.10%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
--
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
--
Mr. Kenneth T. (Ken) Mills
Mr. Kenneth T. (Ken) Mills
Chairman of the Board
Chairman of the Board
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
45.81K
-165.45%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
22.06K
+9.10%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qua, 13 de mai
Atualizado em: qua, 13 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Redmile Group, LLC
8.46%
BlackRock Institutional Trust Company, N.A.
7.73%
Fox (Allan Mark)
5.62%
State Street Investment Management (US)
5.29%
JP Morgan Asset Management
4.91%
Outro
67.98%
Investidores
Investidores
Proporção
Redmile Group, LLC
8.46%
BlackRock Institutional Trust Company, N.A.
7.73%
Fox (Allan Mark)
5.62%
State Street Investment Management (US)
5.29%
JP Morgan Asset Management
4.91%
Outro
67.98%
Tipos de investidores
Investidores
Proporção
Investment Advisor
31.72%
Investment Advisor/Hedge Fund
31.68%
Hedge Fund
8.28%
Research Firm
8.11%
Individual Investor
7.56%
Private Equity
0.97%
Corporation
0.53%
Bank and Trust
0.37%
Family Office
0.36%
Outro
10.43%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
410
45.28M
87.72%
-3.48M
2025Q4
409
42.94M
84.82%
-6.24M
2025Q3
403
44.05M
87.32%
-5.71M
2025Q2
421
48.19M
95.62%
-3.63M
2025Q1
446
48.46M
96.35%
-3.90M
2024Q4
444
48.16M
97.22%
-4.82M
2024Q3
444
49.64M
100.43%
-4.45M
2024Q2
437
49.30M
99.98%
-3.20M
2024Q1
451
48.23M
99.21%
+414.63K
2023Q4
436
43.62M
98.84%
-7.14M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Redmile Group, LLC
4.37M
8.46%
-324.58K
-6.92%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
3.99M
7.73%
-165.79K
-3.99%
Dec 31, 2025
Fox (Allan Mark)
2.90M
5.62%
+7.77K
+0.27%
May 30, 2025
State Street Investment Management (US)
2.29M
4.43%
+301.86K
+15.21%
Dec 31, 2025
JP Morgan Asset Management
2.53M
4.91%
-76.70K
-2.94%
Dec 31, 2025
Morgan Stanley & Co. LLC
1.74M
3.38%
+296.91K
+20.55%
Dec 31, 2025
Goldman Sachs & Company, Inc.
1.52M
2.95%
-96.48K
-5.95%
Dec 31, 2025
AQR Capital Management, LLC
1.36M
2.64%
+72.31K
+5.61%
Dec 31, 2025
Integral Health Asset Management, LLC
1.20M
2.33%
+100.00K
+9.09%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
WisdomTree BioRevolution Fund
2.25%
iShares Neuroscience and Healthcare ETF
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Global X Genomics & Biotechnology ETF
0.65%
JPMorgan Fundamental Data Science Small Core ETF
0.45%
ALPS Medical Breakthroughs ETF
0.27%
State Street SPDR S&P Biotech ETF
0.24%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Fidelity Enhanced Small Cap ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.08%
Ver Mais
WisdomTree BioRevolution Fund
Proporção2.25%
iShares Neuroscience and Healthcare ETF
Proporção1.02%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.85%
Global X Genomics & Biotechnology ETF
Proporção0.65%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.45%
ALPS Medical Breakthroughs ETF
Proporção0.27%
State Street SPDR S&P Biotech ETF
Proporção0.24%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.13%
Fidelity Enhanced Small Cap ETF
Proporção0.12%
ProShares Ultra Nasdaq Biotechnology
Proporção0.08%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
